Besides the so-called “unfilled prescriptions” what other threats face Acthar? Continued payer scrutiny from both a pricing and efficacy view, and potential competition from other agents and synthetic acth are primary. Oh, and the stellar management by MelonHead. Anything else? Which division will see the biggest year over year decline in sales?
Don’t believe all that, MNK is a wonderful company with top notch leadership in every sector! Yes, take the job here!
OP - I am not interviewing, I work here, and I think Acthar has a place when used in the proper setting. I think the “unfilled” comment from Mark is hilarious. I also have some thoughts on which division is going in the shitter. Just curios if others share my thoughts. And it aounds like none of those reponding are actually (still) with MNK. Anyone else been warned about posting on CP?
